Imatinib Mesylate in the Treatment of Chronic Myelogenous Leukemia

スポンサーリンク

概要

• 論文の詳細を見る
• 2004-06-15

著者

• Cortes Jorge

  Department Of Leukemia M.d. Anderson Cancer Center

• Cortes Jorge

  Department Of Leukemia University Of Texas M. D. Anderson Cancer Center

• BORTHAKUR Gautam

  Department of Leukemia, University of Texas M. D. Anderson Cancer Center

• Borthakur Gautam

  Department Of Leukemia University Of Texas M. D. Anderson Cancer Center

関連論文

• Incidence of extramedullary disease in patients with acute promyelocytic leukemia : a single-institution experience
• Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation
• Imatinib mesylate therapy for polycythemia vera : final result of a phase II study initiated in 2001
• The JAK kinase inhibitor CP-690,550 supresses the growth of human polycythemia vera cells carrying the JAK2^ mutation
• Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406
• New Strategies in Chronic Myeloid Leukemia
• Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays
• Imatinib Mesylate in the Treatment of Chronic Myelogenous Leukemia

スポンサーリンク